<style type="text/css"> .wpb_animate_when_almost_visible { opacity: 1; }</style>
  • Using technology in tumor genomics to develop precision cancer therapeutics

    Investor Relations

Press Releases

Archives: Search / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

2016 Archives

Nov 30, 2016
Companies to develop and commercialize multiplexed urine and blood ctDNA liquid biopsy assay kits for global distribution
Oct 4, 2016
Trovera™ liquid biopsy test selected by the Pancreatic Cancer Action Network for its industry-leading sensitivity and ability to rapidly and quantitatively assess response to therapy
Aug 17, 2016
BCBS Illinois expands patient access to Trovera™ tests for 8.1 million covered lives
Aug 9, 2016
Author concludes that confirmation of EGFR mutational status using urine ctDNA analysis should be considered in treatment decision-making
Jul 26, 2016
Data confirms EGFR Activating Mutations and EGFR T790M in metastatic non-small cell lung cancer (NSCLC) diagnosis in urine and blood with high sensitivity and specificity
Jul 6, 2016
Trovagene's KRAS ctDNA liquid biopsy test will be at the forefront of research partnership with Dr. Diane Simeone at University of Michigan Health System
Jun 6, 2016
Results validate urine ctDNA testing as an alternative to tissue and plasma based on a large prospective study of T790M detection and patient response to an EGFR tyrosine kinase inhibitor
May 19, 2016
Results from 213 patient study demonstrates use of urinary ctDNA as a stand-alone test for the highly sensitive detection of EGFR T790M mutations for therapy selection
May 13, 2016
92.9% of metastatic pancreatic cancer patients determined to be KRAS positive using Trovagene's Precision Cancer Monitoring assay

email print rss
Wistia video thumbnail - Susann-Berz Patient Video- Home Page

Thanks for reporting a problem. We'll attach technical data about this session to help us figure out the issue. Which of these best describes the problem?

Any other details or context?